Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference
07 Febrero 2024 - 6:00AM
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company
dedicated to advancing neurogenetic medicines, today announced that
Chief Financial Officer Peter Pfreundschuh will present at the
Oppenheimer Life Sciences Conference on February 14, 2024, at 11:20
a.m. ET.
A webcast of the presentation may be accessed from the Investors
section of Voyager’s website at ir.voyagertherapeutics.com. A
replay of the webcast will be archived on the Company's website for
at least 30 days.
About Voyager TherapeuticsVoyager
Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company
dedicated to leveraging the power of human genetics to modify the
course of – and ultimately cure – neurological diseases. Our
pipeline includes programs for Alzheimer’s disease, amyotrophic
lateral sclerosis (ALS), Parkinson’s disease, and multiple other
diseases of the central nervous system. Many of our programs are
derived from our TRACER™ AAV capsid discovery platform, which we
have used to generate novel capsids and identify associated
receptors to potentially enable high brain penetration with genetic
medicines following intravenous dosing. Some of our programs are
wholly owned, and some are advancing with partners including
Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine
Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more
information, visit www.voyagertherapeutics.com.
Voyager Therapeutics® is a registered trademark, and TRACER™ is
a trademark, of Voyager Therapeutics, Inc.
Contacts
Trista Morrison, NACD.DC, tmorrison@vygr.com
Investors: Adam Bero, Ph.D., abero@kendallir.com
Media: Brooke Shenkin, brooke@scientpr.com
Voyager Therapeutics (NASDAQ:VYGR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Voyager Therapeutics (NASDAQ:VYGR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024